

9 **Name of Journal:** *World Journal of Clinical Cases*

Manuscript NO: 55463

Manuscript Type: CASE REPORT

Lenvatinib for large hepatocellular carcinomas with portal trunk invasion:

Two case reports

Satoshi Komiyama, Kazushi Numata, Satoshi Moriya, Hiroyuki Fukuda,
Makoto Chuma, Shin Maeda

Abstract

BACKGROUND

In a phase III trial of lenvatinib as first-line treatment for advanced unresectable hepatocellular carcinoma (uHCC), the drug proved non-inferior to sorafenib in

Match Overview

1	Internet 25 words crawled on 03-Mar-2011 www.radcliffe-oxford.com	1%
2	Internet 24 words crawled on 26-Feb-2020 hbsn.amegroups.com	1%
3	Internet 24 words crawled on 29-Nov-2017 link.springer.com	1%
4	Internet 19 words crawled on 16-May-2020 worldwidescience.org	1%
5	Internet 16 words crawled on 02-Aug-2019 clinicaltrials.gov	<1%
6	Crossref 15 words Chuma, Uojima, Numata, Hidaka et al. "Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive ..."	<1%
7	Internet 15 words crawled on 10-Mar-2020 www.frontiersin.org	<1%
	Internet 14 words	



国内版 国际版

Lenvatinib for two cases of large hepatocellular carcinom

ALL IMAGES VIDEOS

26,500 Results Any time

Three criteria for radiological response on survival in ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/hepr.13416>

Jul 26, 2019 · Aim **Lenvatinib (LEN)** is a newly approved, multikinase inhibitor for **treating unresectable hepatocellular carcinoma**. In the present study, we investigated the impact of **three different criteria** ...

Cited by: 1 **Author:** Shun Kaneko, Kaoru Tsuchiya, Masayuki ...

Publish Year: 2020

Hepatocellular Carcinoma with Macrovascular Invasion ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704715>

Oct 19, 2017 · **Hepatic resection** as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, **multiple tumors**, or **macrovascular invasion**. **Medicine (Baltimore)** 2015; 94:e396. [PMC free article] [PubMed] [Google Scholar]

Cited by: 11 **Author:** Charlotte E. Costentin, Cristina R. Ferron...

Publish Year: 2017

Preoperative Stereotactic Body Radiotherapy to Portal Vein ...

<https://www.nature.com/articles/s41598-020-60871-0>

Successful **preoperative treatment** for hepatocellular carcinoma with **tumor thrombus** in the **major portal branch** by **three-dimensional conformal radiation therapy**—two case reports.

Lenvatinib May Drastically Change the Treatment Landscape ...

<https://www.researchgate.net/publication/323212333...>

Importance Sorafenib is the **first-line treatment** for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit

Chat with Bing



Am I the most talkative search engine you have ever used?

Say something...

Lenvatinib for large hepatocellular carcinomas with porta



ALL

IMAGES

VIDEOS

26,600 Results

Any time ▾

[Clinical features of lenvatinib for unresectable ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346240>

Dec 21, 2018 · 1. INTRODUCTION. For treatment of unresectable **hepatocellular carcinoma** (u-HCC), tyrosine kinase inhibitors (TKIs), such as sorafenib (SOR) 1, 2 and regorafenib (REG), 3, 4 have been introduced. SOR was developed as a first-line agent for u-HCC, while REG is used as second-line therapy in patients who show good tolerability and progressive disease (PD) with SOR.

Cited by: 21**Author:** Atsushi Hiraoka, Takashi Kumada, Kazuy...**Publish Year:** 2019

[Hepatocellular Carcinoma with Macrovascular Invasion ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704715>

Introduction. Tumoral macrovascular **invasion** (MVI) of hepatic and/or **portal** vein branches is common during the natural history of **hepatocellular carcinoma** (HCC) and significantly reduces median survival when compared to patients without MVI [1, 2]. Current international guidelines recommend sorafenib as the only treatment option in **case** of MVI [3, 4, 5].

Cited by: 12**Author:** Charlotte E. Costentin, Cristina R. Ferron...**Publish Year:** 2017

[Three criteria for radiological response on survival in ...](#)

<https://onlinelibrary.wiley.com/doi/10.1111/hepr.13416>

Jul 26, 2019 · Introduction. **Lenvatinib** (LEN) is a multikinase inhibitor of vascular endothelial growth factor receptors 1–3, fibroblast growth factor 1–4, platelet-derived growth factor receptor- α , RET, and KIT. 1-3 Results from the REFLECT study of LEN versus sorafenib (SOR), carried out with patients with unresectable **hepatocellular carcinoma** (HCC), showed that LEN met its primary end-point by ...



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

26,600 Results

Any time ▾

Three criteria for radiological ... - Wiley Online Library

<https://onlinelibrary.wiley.com/doi/full/10.1111/hepr.13416>

Jul 26, 2019 · Introduction. **Lenvatinib** (LEN) is a multikinase inhibitor of vascular endothelial growth factor receptors 1–3, fibroblast growth factor 1–4, platelet-derived growth factor receptor- α , RET, and KIT. 1-3 Results from the REFLECT study of LEN versus sorafenib (SOR), carried out with patients with unresectable **hepatocellular carcinoma** (HCC), showed that LEN met its primary end-point by ...

Cited by: 1

Author: Shun Kaneko, Kaoru Tsuchiya, Masayuki ...

Publish Year: 2020

Clinical features of lenvatinib for unresectable ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346240>

Dec 21, 2018 · 1. INTRODUCTION. For treatment of unresectable **hepatocellular carcinoma** (u-HCC), tyrosine kinase inhibitors (TKIs), such as sorafenib (SOR) 1, 2 and regorafenib (REG), 3, 4 have been introduced. SOR was developed as a first-line agent for u-HCC, while REG is used as second-line therapy in patients who show good tolerability and progressive disease (PD) with SOR.

Cited by: 21

Author: Atsushi Hiraoka, Takashi Kumada, Kazuy...

Publish Year: 2019

Lenvatinib versus sorafenib in first-line ... - The Lancet

[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(18\)30207-1/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30207-1/fulltext)

Based on individual model-derived predicted **lenvatinib** area under the curve (AUC) values at steady state for patients with **hepatocellular carcinoma** in our study, the median values and ranges of AUC between the group with a starting dose of 8 mg for bodyweight less than 60 kg (median 1820·2 ng·h/mL, range 704·8–4980·7) and the group with a ...

Cited by: 639

Author: Masatoshi Kudo, Richard S. Finn, Shukui...

Publish Year: 2018

(PDF) Long-term antitumor effect of lenvatinib on ...

<https://www.researchgate.net/publication/329314061...>